Salem Fevrier

This inventor holds 10 USPTO granted patents and 6 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Schering Corporation, Schering-Plough Corporation. Active years: 2010-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Salem Fevrier. Retrieved from https://idiyas.com/inventor/salem-fevrier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 10

% Patents Active = 50.0

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 16.2

ph-index = 2

Forward Citations = 18(Granted Patents)

Company Filing History:

8 out of 2,405

Merck Sharp + Dohme Corp.

Schering-Plough Corporation

patents

Years Active: 2010-2016

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9469615 - [object Object] (2016-10-18),

2. 9290453 - [object Object] (2016-03-22),

3. 9233979 - Compounds that are ERK inhibitors (2016-01-12),

4. 9226922 - Compounds that are ERK inhibitors (2016-01-05),

5. 9023865 - Compounds that are ERK inhibitors (2015-05-05),

6. 8569312 - Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators (2013-10-29),

7. 8476274 - Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators (2013-07-02),

8. 8324213 - Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators (2012-12-04),

9. 7803828 - Functionally selective alpha2C adrenoreceptor agonists (2010-09-28),

10. 7700592 - α2C adrenoreceptor agonists (2010-04-20),

Title: Salem Fevrier: Innovator in Pharmaceutical Chemistry

Introduction

Salem Fevrier is a notable inventor based in Cranford, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 10 patents. His work primarily focuses on the development of compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents, one invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), along with their pharmaceutically acceptable salts. This invention also includes pharmaceutical compositions comprising such compounds and methods for treating diseases associated with uncontrolled or inappropriate stimulation of CRTH function. Another recent patent involves certain quinolines and aza-quinolines of the Formula (I), similarly detailing their pharmaceutically acceptable salts and therapeutic applications.

Career Highlights

Salem Fevrier has worked with prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme Corp. and Schering-Plough Corporation. His experience in these organizations has allowed him to develop innovative solutions in drug formulation and therapeutic applications.

Collaborations

Throughout his career, Salem has collaborated with notable professionals in the field, including Christopher W. Boyce and Kevin D. McCormick. These collaborations have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Salem Fevrier's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor in the industry. His work continues to pave the way for advancements in therapeutic treatments.

Profile summary based on public USPTO records.